
Faculty, Staff and Student Publications
Publication Date
5-2-2024
Journal
Nature Communications
Abstract
With improvements in survival for patients with metastatic cancer, long-term local control of brain metastases has become an increasingly important clinical priority. While consensus guidelines recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (≤3 cm) treated with SRS alone elicit variable responses. To determine factors influencing this variable response to SRS, we analyzed outcomes of brain metastases ≤3 cm diameter in patients with no prior systemic therapy treated with frame-based single-fraction SRS. Following SRS, 259 out of 1733 (15%) treated lesions demonstrated MRI findings concerning for local treatment failure (LTF), of which 202 /1733 (12%) demonstrated LTF and 54/1733 (3%) had an adverse radiation effect. Multivariate analysis demonstrated tumor size (>1.5 cm) and melanoma histology were associated with higher LTF rates. Our results demonstrate that brain metastases ≤3 cm are not uniformly responsive to SRS and suggest that prospective studies to evaluate the effect of SRS alone or in combination with surgery on brain metastases ≤3 cm matched by tumor size and histology are warranted. These studies will help establish multi-disciplinary treatment guidelines that improve local control while minimizing radiation necrosis during treatment of brain metastasis ≤3 cm.
Keywords
Radiosurgery, Humans, Brain Neoplasms, Male, Female, Middle Aged, Aged, Magnetic Resonance Imaging, Melanoma, Adult, Treatment Outcome, Tumor Burden, Aged, 80 and over, Treatment Failure, Retrospective Studies, Oncology, CNS cancer
DOI
10.1038/s41467-024-47998-8
PMID
38697991
PMCID
PMC11066027
PubMedCentral® Posted Date
May 2024
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes

- Citations
- Citation Indexes: 5
- Usage
- Downloads: 14
- Abstract Views: 3
- Captures
- Readers: 15
- Mentions
- News Mentions: 5
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons